{"pmid":32360286,"title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.","text":["Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.","BACKGROUND: The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. OBJECTIVE: To identify biomarkers for disease severity and progression of COVID-19. METHODS: Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe and 14 moderate patients were measured and analyzed in combination with clinical data. RESULTS: Fourteen cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IP-10, MCP-3, HGF, MIG and MIP-1alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the five cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IP-10 and MCP-3 were excellent predictors for the progression of COVID-19, and the combination of the two cytokines showed the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC) calculations with a value of 0.99. CONCLUSION: In this study, we report biomarkers that highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, and provide potential therapeutic targets and strategies.","J Allergy Clin Immunol","Yang, Yang","Shen, Chenguang","Li, Jinxiu","Yuan, Jing","Wei, Jinli","Huang, Fengmin","Wang, Fuxiang","Li, Guobao","Li, Yanjie","Xing, Li","Peng, Ling","Yang, Minghui","Cao, Mengli","Zheng, Haixia","Wu, Weibo","Zou, Rongrong","Li, Delin","Xu, Zhixiang","Wang, Haiyan","Zhang, Mingxia","Zhang, Zheng","Gao, George F","Jiang, Chengyu","Liu, Lei","Liu, Yingxia","32360286"],"abstract":["BACKGROUND: The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. OBJECTIVE: To identify biomarkers for disease severity and progression of COVID-19. METHODS: Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe and 14 moderate patients were measured and analyzed in combination with clinical data. RESULTS: Fourteen cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IP-10, MCP-3, HGF, MIG and MIP-1alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the five cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IP-10 and MCP-3 were excellent predictors for the progression of COVID-19, and the combination of the two cytokines showed the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC) calculations with a value of 0.99. CONCLUSION: In this study, we report biomarkers that highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, and provide potential therapeutic targets and strategies."],"journal":"J Allergy Clin Immunol","authors":["Yang, Yang","Shen, Chenguang","Li, Jinxiu","Yuan, Jing","Wei, Jinli","Huang, Fengmin","Wang, Fuxiang","Li, Guobao","Li, Yanjie","Xing, Li","Peng, Ling","Yang, Minghui","Cao, Mengli","Zheng, Haixia","Wu, Weibo","Zou, Rongrong","Li, Delin","Xu, Zhixiang","Wang, Haiyan","Zhang, Mingxia","Zhang, Zheng","Gao, George F","Jiang, Chengyu","Liu, Lei","Liu, Yingxia"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360286","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jaci.2020.04.027","keywords":["covid-19","sars-cov-2","biomarkers","disease progression","prediction"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138495490457603,"score":9.490897,"similar":[{"pmid":32490680,"title":"Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19.","text":["Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19.","Aim: We aimed to explore the biomarkers for disease progression or the risk of nonsurvivors. Materials & methods: This study included 134 hospitalized patients with confirmed COVID-19 infection. The outcome of moderate versus severe versus critically ill patients and survivors versus nonsurvivors were compared. Results: An increase in the severity of COVID-19 pneumonia was positively associated with lower levels of platelets and albumin (all p < 0.05). In the critical group, the plasma levels of albumin continued to have a significant association for the risk of nonsurvivors (p < 0.05), even after adjusting for confounding factors. Conclusion: Albumin levels could be used as an independent predictor of the risk of nonsurvivors in critically ill patients with COVID-19.","Biomark Med","Li, Juyi","Li, Meng","Zheng, Shasha","Li, Menglan","Zhang, Minghua","Sun, Minxian","Li, Xiang","Deng, Aiping","Cai, Yi","Zhang, Hongmei","32490680"],"abstract":["Aim: We aimed to explore the biomarkers for disease progression or the risk of nonsurvivors. Materials & methods: This study included 134 hospitalized patients with confirmed COVID-19 infection. The outcome of moderate versus severe versus critically ill patients and survivors versus nonsurvivors were compared. Results: An increase in the severity of COVID-19 pneumonia was positively associated with lower levels of platelets and albumin (all p < 0.05). In the critical group, the plasma levels of albumin continued to have a significant association for the risk of nonsurvivors (p < 0.05), even after adjusting for confounding factors. Conclusion: Albumin levels could be used as an independent predictor of the risk of nonsurvivors in critically ill patients with COVID-19."],"journal":"Biomark Med","authors":["Li, Juyi","Li, Meng","Zheng, Shasha","Li, Menglan","Zhang, Minghua","Sun, Minxian","Li, Xiang","Deng, Aiping","Cai, Yi","Zhang, Hongmei"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490680","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2217/bmm-2020-0254","keywords":["covid-19","albumin","biomarkers","critically ill patients","infection","pneumonia"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668623433569665025,"score":245.9994},{"pmid":32365221,"title":"Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19.","text":["Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19.","BACKGROUND: Effective laboratory markers for estimation of disease severity and predicting the clinical progression of coronavirus disease-2019 (COVID-19) is urgent needed. METHODS: The laboratory tests including blood routine, cytokine profiles and infection markers were collected from 389 confirmed COVID-19 patients. RESULTS: The included patients were classified into mild (n=168), severe (n=169) and critical groups (n=52). The leukocytes, neutrophils, infection biomarkers (such as CRP, PCT and ferritin) and the concentrations of cytokines (IL-2R, IL-6, IL-8, IL-10 and TNF-alpha) were significantly increased while lymphocytes were significantly decreased with increased severity of illness. The amounts of IL-2R was positively correlated with the other cytokines and negatively correlated with lymphocyte number. The ratio of IL-2R to lymphocytes was found remarkably increased in severe and critical patients. IL-2R/lymphocyte was superior compared with other markers for the identification of COVID-19 with critical illness not only from mild but also from severe illness. Moreover, the cytokine profiles and IL-2R/lymphocyte were significantly decreased in recovered patients but further increased in disease deteriorated patients, which might be correlated with the outcome of COVID-19. CONCLUSIONS: Lymphopenia and increased levels of cytokines were closely associated with the disease severity. IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease.","Clin Exp Immunol","Hou, Hongyan","Zhang, Bo","Huang, Hui","Luo, Ying","Wu, Shiji","Tang, Guoxing","Liu, Weiyong","Mao, Lie","Mao, Liyan","Wang, Feng","Sun, Ziyong","32365221"],"abstract":["BACKGROUND: Effective laboratory markers for estimation of disease severity and predicting the clinical progression of coronavirus disease-2019 (COVID-19) is urgent needed. METHODS: The laboratory tests including blood routine, cytokine profiles and infection markers were collected from 389 confirmed COVID-19 patients. RESULTS: The included patients were classified into mild (n=168), severe (n=169) and critical groups (n=52). The leukocytes, neutrophils, infection biomarkers (such as CRP, PCT and ferritin) and the concentrations of cytokines (IL-2R, IL-6, IL-8, IL-10 and TNF-alpha) were significantly increased while lymphocytes were significantly decreased with increased severity of illness. The amounts of IL-2R was positively correlated with the other cytokines and negatively correlated with lymphocyte number. The ratio of IL-2R to lymphocytes was found remarkably increased in severe and critical patients. IL-2R/lymphocyte was superior compared with other markers for the identification of COVID-19 with critical illness not only from mild but also from severe illness. Moreover, the cytokine profiles and IL-2R/lymphocyte were significantly decreased in recovered patients but further increased in disease deteriorated patients, which might be correlated with the outcome of COVID-19. CONCLUSIONS: Lymphopenia and increased levels of cytokines were closely associated with the disease severity. IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease."],"journal":"Clin Exp Immunol","authors":["Hou, Hongyan","Zhang, Bo","Huang, Hui","Luo, Ying","Wu, Shiji","Tang, Guoxing","Liu, Weiyong","Mao, Lie","Mao, Liyan","Wang, Feng","Sun, Ziyong"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32365221","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/cei.13450","keywords":["covid-19","il-2r/lymphocyte ratio","sars-cov-2","clinical progression","cytokine"],"locations":["Lymphopenia"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138496044105728,"score":244.26387},{"pmid":32352397,"title":"The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study.","text":["The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study.","Objectives In December 2019, there was an outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, and since then, the disease has been increasingly spread throughout the world. Unfortunately, the information about early prediction factors for disease progression is relatively limited. Therefore, there is an urgent need to investigate the risk factors of developing severe disease. The objective of the study was to reveal the risk factors of developing severe disease by comparing the differences in the hemocyte count and dynamic profiles in patients with severe and non-severe COVID-19. Methods In this retrospectively analyzed cohort, 141 confirmed COVID-19 patients were enrolled in Taizhou Public Health Medical Center, Taizhou Hospital, Zhejiang Province, China, from January 17, 2020 to February 26, 2020. Clinical characteristics and hemocyte counts of severe and non-severe COVID patients were collected. The differences in the hemocyte counts and dynamic profiles in patients with severe and non-severe COVID-19 were compared. Multivariate Cox regression analysis was performed to identify potential biomarkers for predicting disease progression. A concordance index (C-index), calibration curve, decision curve and the clinical impact curve were calculated to assess the predictive accuracy. Results The data showed that the white blood cell count, neutrophil count and platelet count were normal on the day of hospital admission in most COVID-19 patients (87.9%, 85.1% and 88.7%, respectively). A total of 82.8% of severe patients had lymphopenia after the onset of symptoms, and as the disease progressed, there was marked lymphopenia. Multivariate Cox analysis showed that the neutrophil count (hazard ratio [HR] = 4.441, 95% CI = 1.954-10.090, p = 0.000), lymphocyte count (HR = 0.255, 95% CI = 0.097-0.669, p = 0.006) and platelet count (HR = 0.244, 95% CI = 0.111-0.537, p = 0.000) were independent risk factors for disease progression. The C-index (0.821 [95% CI, 0.746-0.896]), calibration curve, decision curve and the clinical impact curve showed that the nomogram can be used to predict the disease progression in COVID-19 patients accurately. In addition, the data involving the neutrophil count, lymphocyte count and platelet count (NLP score) have something to do with improving risk stratification and management of COVID-19 patients. Conclusions We designed a clinically predictive tool which is easy to use for assessing the progression risk of COVID-19, and the NLP score could be used to facilitate patient stratification management.","Clin Chem Lab Med","Zheng, Yufen","Zhang, Ying","Chi, Hongbo","Chen, Shiyong","Peng, Minfei","Luo, Lifei","Chen, Linping","Li, Jun","Shen, Bo","Wang, Donglian","32352397"],"abstract":["Objectives In December 2019, there was an outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, and since then, the disease has been increasingly spread throughout the world. Unfortunately, the information about early prediction factors for disease progression is relatively limited. Therefore, there is an urgent need to investigate the risk factors of developing severe disease. The objective of the study was to reveal the risk factors of developing severe disease by comparing the differences in the hemocyte count and dynamic profiles in patients with severe and non-severe COVID-19. Methods In this retrospectively analyzed cohort, 141 confirmed COVID-19 patients were enrolled in Taizhou Public Health Medical Center, Taizhou Hospital, Zhejiang Province, China, from January 17, 2020 to February 26, 2020. Clinical characteristics and hemocyte counts of severe and non-severe COVID patients were collected. The differences in the hemocyte counts and dynamic profiles in patients with severe and non-severe COVID-19 were compared. Multivariate Cox regression analysis was performed to identify potential biomarkers for predicting disease progression. A concordance index (C-index), calibration curve, decision curve and the clinical impact curve were calculated to assess the predictive accuracy. Results The data showed that the white blood cell count, neutrophil count and platelet count were normal on the day of hospital admission in most COVID-19 patients (87.9%, 85.1% and 88.7%, respectively). A total of 82.8% of severe patients had lymphopenia after the onset of symptoms, and as the disease progressed, there was marked lymphopenia. Multivariate Cox analysis showed that the neutrophil count (hazard ratio [HR] = 4.441, 95% CI = 1.954-10.090, p = 0.000), lymphocyte count (HR = 0.255, 95% CI = 0.097-0.669, p = 0.006) and platelet count (HR = 0.244, 95% CI = 0.111-0.537, p = 0.000) were independent risk factors for disease progression. The C-index (0.821 [95% CI, 0.746-0.896]), calibration curve, decision curve and the clinical impact curve showed that the nomogram can be used to predict the disease progression in COVID-19 patients accurately. In addition, the data involving the neutrophil count, lymphocyte count and platelet count (NLP score) have something to do with improving risk stratification and management of COVID-19 patients. Conclusions We designed a clinically predictive tool which is easy to use for assessing the progression risk of COVID-19, and the NLP score could be used to facilitate patient stratification management."],"journal":"Clin Chem Lab Med","authors":["Zheng, Yufen","Zhang, Ying","Chi, Hongbo","Chen, Shiyong","Peng, Minfei","Luo, Lifei","Chen, Linping","Li, Jun","Shen, Bo","Wang, Donglian"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352397","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1515/cclm-2020-0377","keywords":["covid-19","disease progression","lymphocyte count","neutrophil count","platelet count"],"locations":["Wuhan","China","Taizhou Hospital","Zhejiang","China","neutrophil","neutrophil","neutrophil"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495678152705,"score":218.16887},{"pmid":32414383,"title":"Plasma CRP level is positively associated with the severity of COVID-19.","text":["Plasma CRP level is positively associated with the severity of COVID-19.","AIMS: The coronavirus disease 2019 (COVID-19) is characterized as highly contagious and deadly; however there is no credible and convenient biomarker to predict the severity of the disease. The aim of the present study was to estimate whether the CRP level is able to act as a marker in indicating the severity of COVID-19. METHODS: Patients who complained cough or chest pain with or without fever were enrolled after laboratory confirmed of SARS-CoV-2 viral nucleic acid via qRT-PCR. Chest computed tomography (CT) was then performed to classify the patients into mild, moderate and severe pneumonia groups according to the interim management guideline. Then linear regression models were applied to analyze the association between c-reactive protein (CRP) levels and severity of COVID-19 pneumonia. RESULTS: When compared to mild pneumonia, the adjusted-Odds Ratio were 11.46, p = 0.029 and 23.40, p = 0.025 in moderate and severe pneumonia, respectively. The area under receiver operation curve was 0.898 (95% CI 0.835, 0.962, p < 0.001). Higher plasma CRP level indicated severe COVID-19 pneumonia and longer inpatients duration. CONCLUSIONS: The level of plasma CRP was positively correlated to the severity of COVID-19 pneumonia. Our findings could assist to discern patients of moderate to severe COVID-19 pneumonia from the mild ones. Our findings may be useful as an earlier indicator for severe illness and help physicians to stratify patients for intense care unit transfer.","Ann Clin Microbiol Antimicrob","Chen, Wei","Zheng, Kenneth I","Liu, Saiduo","Yan, Zhihan","Xu, Chongyong","Qiao, Zengpei","32414383"],"abstract":["AIMS: The coronavirus disease 2019 (COVID-19) is characterized as highly contagious and deadly; however there is no credible and convenient biomarker to predict the severity of the disease. The aim of the present study was to estimate whether the CRP level is able to act as a marker in indicating the severity of COVID-19. METHODS: Patients who complained cough or chest pain with or without fever were enrolled after laboratory confirmed of SARS-CoV-2 viral nucleic acid via qRT-PCR. Chest computed tomography (CT) was then performed to classify the patients into mild, moderate and severe pneumonia groups according to the interim management guideline. Then linear regression models were applied to analyze the association between c-reactive protein (CRP) levels and severity of COVID-19 pneumonia. RESULTS: When compared to mild pneumonia, the adjusted-Odds Ratio were 11.46, p = 0.029 and 23.40, p = 0.025 in moderate and severe pneumonia, respectively. The area under receiver operation curve was 0.898 (95% CI 0.835, 0.962, p < 0.001). Higher plasma CRP level indicated severe COVID-19 pneumonia and longer inpatients duration. CONCLUSIONS: The level of plasma CRP was positively correlated to the severity of COVID-19 pneumonia. Our findings could assist to discern patients of moderate to severe COVID-19 pneumonia from the mild ones. Our findings may be useful as an earlier indicator for severe illness and help physicians to stratify patients for intense care unit transfer."],"journal":"Ann Clin Microbiol Antimicrob","authors":["Chen, Wei","Zheng, Kenneth I","Liu, Saiduo","Yan, Zhihan","Xu, Chongyong","Qiao, Zengpei"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414383","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s12941-020-00362-2","keywords":["crp","ct","pneumonia","sars-cov-2","severity"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666991242716643330,"score":191.03891},{"pmid":32501293,"title":"Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.","text":["Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.","Background Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalised COVID-19 patients from serial sampling and follow up over four weeks.Methods A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You'an hospital in China with either mild (53 patients) or severe disease (18 patients) were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines and chemokines in peripheral blood every 4-7 days over one month per patient using a bio-plex multiplex immunoassay.Results We found that the chemokine RANTES(CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1Ra and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF- alpha and GM-CSF showed no significant differences between severe and mild cases.Conclusion Together our data suggest early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1Ra, IL-10 in blood individually and in combination might be useful prognostic bio-markers to guide treatment strategies.","JCI Insight","Zhao, Yan","Qin, Ling","Zhang, Ping","Li, Kang","Liang, Lianchun","Sun, Jianping","Xu, Bin","Dai, Yanchao","Li, Xuemei","Zhang, Chi","Peng, Yanchun","Feng, Yingmei","Li, Ang","Hu, Zhongjie","Xiang, Haiping","Ogg, Graham","Ho, Ling-Pei","McMichael, Andrew J","Jin, Ronghua","Knight, Julian C","Dong, Tao","Zhang, Yonghong","32501293"],"abstract":["Background Identifying immune correlates of COVID-19 disease severity is an urgent need for clinical management, vaccine evaluation and drug development. Here we present a temporal analysis of key immune mediators, cytokine and chemokines in blood of hospitalised COVID-19 patients from serial sampling and follow up over four weeks.Methods A total of 71 patients with laboratory-confirmed COVID-19 admitted to Beijing You'an hospital in China with either mild (53 patients) or severe disease (18 patients) were enrolled with 18 healthy volunteers. We measured 34 immune mediators, cytokines and chemokines in peripheral blood every 4-7 days over one month per patient using a bio-plex multiplex immunoassay.Results We found that the chemokine RANTES(CCL5) was significantly elevated, from an early stage of the infection, in patients with mild but not severe disease. We also found that early production of inhibitory mediators including IL-10 and IL-1RA were significantly associated with disease severity, and a combination of CCL5, IL-1Ra and IL-10 at week 1 may predict patient outcomes. The majority of cytokines that are known to be associated with the cytokine storm in virus infections such as IL-6 and IFN-gamma were only significantly elevated in the late stage of severe COVID-19 illness. TNF- alpha and GM-CSF showed no significant differences between severe and mild cases.Conclusion Together our data suggest early intervention to increase expression of CCL5 may prevent patients from developing severe illness. Our data also suggest that measurement of levels of CCL5, as well as IL-1Ra, IL-10 in blood individually and in combination might be useful prognostic bio-markers to guide treatment strategies."],"journal":"JCI Insight","authors":["Zhao, Yan","Qin, Ling","Zhang, Ping","Li, Kang","Liang, Lianchun","Sun, Jianping","Xu, Bin","Dai, Yanchao","Li, Xuemei","Zhang, Chi","Peng, Yanchun","Feng, Yingmei","Li, Ang","Hu, Zhongjie","Xiang, Haiping","Ogg, Graham","Ho, Ling-Pei","McMichael, Andrew J","Jin, Ronghua","Knight, Julian C","Dong, Tao","Zhang, Yonghong"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501293","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1172/jci.insight.139834","keywords":["adaptive immunity","covid-19"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668804508866576384,"score":186.80408}]}